The atheroma plaque secretome stimulates the mobilization of endothelial progenitor cells ex vivo
Identificadores
URI: http://hdl.handle.net/10498/30489
DOI: 10.1016/j.yjmcc.2017.02.001
ISSN: 0022-2828
Files
Statistics
Metrics and citations
Metadata
Show full item recordAuthor/s
Vega, Francisco M.; Gautier, Violette; Fernández Ponce, Cecilia Matilde
; Extremera, M.J.; Altelaar, A.F.M.; Millan, Jaime; Tellez, Juan C.; Hernandez-Campos, J.A.; Conejero, Rosario; Bolívar Pérez, Jorge
; Pardal, R.; García Cózar, Francisco José
; Aguado Vidal, Enrique
; Heck, Albert J.R.; Durán Ruiz, María del Carmen
Date
2017-02-20Department
Biomedicina, Biotecnología y Salud PúblicaSource
Journal of Molecular and Cellular Cardiology - Vol. 105, Pages 12 - 23Abstract
Endothelial progenitor cells (EPCs) constitute a promising alternative in cardiovascular regenerative medicine
due to their assigned role in angiogenesis and vascular repair. In response to injury, EPCs promote vascular remodeling
by replacement of damaged endothelial cells and/or by secreting angiogenic factors over the damaged
tissue. Nevertheless, such mechanisms need to be further characterized. In the current approach we have evaluated
the initial response of early EPCs (eEPCs) from healthy individuals after direct contact with the factors released
by carotid arteries complicated with atherosclerotic plaques (AP), in order to understand the
mechanisms underlying the neovascularization and remodeling properties assigned to these cells. Herein, we
found that the AP secretome stimulated eEPCs proliferation and mobilization ex vivo, and such increase was accompanied
by augmented permeability, cell contraction and also an increase of cell-cell adhesion in association
with raised vinculin levels. Furthermore, a comparative mass spectrometry analysis of control versus stimulated
eEPCs revealed a differential expression of proteins in the AP treated cells, mostly involved in cell migration, proliferation
and vascular remodeling. Some of these protein changeswere also detected in the eEPCs isolated from
atherosclerotic patients compared to eEPCs from healthy donors.
We have shown, for the first time, that the AP released factors activate eEPCs ex vivo by inducing their mobilization
together with the expression of vasculogenic related markers. The present approach could be taken as a
ex vivo model to study the initial activation of vascular cells in atherosclerosis and also to evaluate strategies
looking to potentiate the mobilization of EPCs prior to clinical applications.
Subjects
Endothelial progenitor cells; Atherosclerosis; Cell therapy; Proteomics; Cell migrationCollections
- Artículos Científicos [11973]
- Articulos Científicos Biomedicina [582]





